{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:50:06Z","timestamp":1791946206339,"version":"4.3.4"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijp.ijp_823_19","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T05:34:07Z","timestamp":1579239247000},"page":"418","source":"Crossref","is-referenced-by-count":23,"title":["Novel therapeutic targets for amyotrophic lateral sclerosis"],"prefix":"10.4103","volume":"51","author":[{"given":"Bikash","family":"Medhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitika","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RahulSoloman","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AmitRaj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.276050-1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2174\/1570159X14666160120152423","article-title":"Current therapy of drugs in amyotrophic lateral sclerosis","author":"Lu","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"key-10.4103\/0253-7613.276050-2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s40262-018-0655-4","article-title":"Two decades-long journey from riluzole to edaravone: Revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics","author":"Dash","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/0253-7613.276050-3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","article-title":"Epidemiology of amyotrophic lateral sclerosis: An update of recent literature","author":"Longinetti","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"key-10.4103\/0253-7613.276050-4","unstructured":"Gourie-Devi M, Rao VN, Prakashi R. Neuroepidemiological study in semi urban and rural areas in South India: Pattern of neurological disorders including motor neurone disease. In: Gourie-Devi M, editor. Motor Neuron Disease: Global Clinical Patterns and International Research. New Delhi: Oxford & IBH; 1987. p. 11-21."},{"key":"key-10.4103\/0253-7613.276050-5","unstructured":"Hancock SM, Iftekhar NT, Jampana SC, Khan M, Mahmud N, Navaneetham D, et al. Rare diseases and disorders: Research, Resource and Repository for South Asia. Available from: http:\/\/www.rarediseasesindia.org\/als. [Last accessed 15 Oct 2019, 6:30 pm]."},{"key":"key-10.4103\/0253-7613.276050-6","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","author":"van","year":"2017","journal-title":"Lancet"},{"key":"key-10.4103\/0253-7613.276050-7","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/jnnp.2004.048652","article-title":"Molecular and cellular pathways of neurodegeneration in motor neurone disease","author":"Shaw","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/0253-7613.276050-8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3389\/fimmu.2017.01005","article-title":"Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"key-10.4103\/0253-7613.276050-9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/WCO.0000000000000599","article-title":"Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis","author":"Thonhoff","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"key-10.4103\/0253-7613.276050-10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14737175.2016.1227705","article-title":"Management and therapeutic perspectives in amyotrophic lateral sclerosis","author":"Mathis","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"key-10.4103\/0253-7613.276050-11","first-page":"CD001447","article-title":"Riluzole for ALS (ALS)\/motor neuron disease (MND)","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0253-7613.276050-12","first-page":"505","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial","author":"Writing","year":"2017","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/0253-7613.276050-13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2013.03.019","article-title":"Mitochondria, motor neurons and aging","author":"Garc\u00eda","year":"2013","journal-title":"J Neurol Sci"},{"key":"key-10.4103\/0253-7613.276050-14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8","article-title":"Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death","author":"Borthwick","year":"1999","journal-title":"Ann Neurol"},{"key":"key-10.4103\/0253-7613.276050-15","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s13311-016-0508-5","article-title":"Enhanced bulbar function in amyotrophic lateral sclerosis: The nuedexta treatment trial","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"key":"key-10.4103\/0253-7613.276050-16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.107.123000","article-title":"Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis","author":"Bordet","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/0253-7613.276050-17","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.neuropharm.2012.02.013","article-title":"Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model","author":"Sunyach","year":"2012","journal-title":"Neuropharmacology"},{"key":"key-10.4103\/0253-7613.276050-18","first-page":"433","article-title":"GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis","author":"Martin","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"key-10.4103\/0253-7613.276050-19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neulet.2013.12.005","article-title":"SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models","author":"Ono","year":"2014","journal-title":"Neurosci Lett"},{"key":"key-10.4103\/0253-7613.276050-20","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/ars.2009.2444","article-title":"Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis","author":"Foran","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"key-10.4103\/0253-7613.276050-21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0896-6273(00)80997-6","article-title":"Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis","author":"Lin","year":"1998","journal-title":"Neuron"},{"key":"key-10.4103\/0253-7613.276050-22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2015.09.019","article-title":"Excitotoxicity in ALS: Overstimulation, or overreaction?","author":"King","year":"2016","journal-title":"Exp Neurol"},{"key":"key-10.4103\/0253-7613.276050-23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/aps.2009.24","article-title":"Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases","author":"Dong","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"key-10.4103\/0253-7613.276050-24","first-page":"29","article-title":"Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons","author":"Van","year":"2000","journal-title":"J Neurol Sci"},{"key":"key-10.4103\/0253-7613.276050-25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-4159.2004.02383.x","article-title":"AMPA receptor activation, but not the accumulation of endogenous extracellular glutamate, induces paralysis and motor neuron death in rat spinal cord in vivo","author":"Corona","year":"2004","journal-title":"J Neurochem"},{"key":"key-10.4103\/0253-7613.276050-26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.61.4.456","article-title":"A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis","author":"Cudkowicz","year":"2003","journal-title":"Neurology"},{"key":"key-10.4103\/0253-7613.276050-27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"key-10.4103\/0253-7613.276050-28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.expneurol.2011.01.017","article-title":"Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms","author":"Nizzardo","year":"2011","journal-title":"Exp Neurol"},{"key":"key-10.4103\/0253-7613.276050-29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/187152710791292648","article-title":"Clinical trials for neuroprotection in ALS","author":"Siciliano","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"key-10.4103\/0253-7613.276050-30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/17482968.2011.584627","article-title":"Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically","author":"Paizs","year":"2011","journal-title":"Amyotroph Lateral Scler"},{"key":"key-10.4103\/0253-7613.276050-31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/17482960903307805","article-title":"A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis","author":"Pascuzzi","year":"2010","journal-title":"Amyotroph Lateral Scler"},{"key":"key-10.4103\/0253-7613.276050-32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.biopha.2018.07.032","article-title":"Aquilariae lignum extract attenuates glutamate-induced neuroexcitotoxicity in HT22 hippocampal cells","author":"Lee","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"key-10.4103\/0253-7613.276050-33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-013-1125-6","article-title":"Protein aggregation in amyotrophic lateral sclerosis","author":"Blokhuis","year":"2013","journal-title":"Acta Neuropathol"},{"key":"key-10.4103\/0253-7613.276050-34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00401-012-1022-4","article-title":"The genetics and neuropathology of amyotrophic lateral sclerosis","author":"Al-Chalabi","year":"2012","journal-title":"Acta Neuropathol"},{"key":"key-10.4103\/0253-7613.276050-35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1471-4159.2008.05595.x","article-title":"Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS","author":"Kalmar","year":"2008","journal-title":"J Neurochem"},{"key":"key-10.4103\/0253-7613.276050-36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuron.2019.03.014","article-title":"Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions","author":"Nussbacher","year":"2019","journal-title":"Neuron"},{"key":"key-10.4103\/0253-7613.276050-37","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1093\/hmg\/ddq137","article-title":"TDP-43 and FUS\/TLS: Emerging roles in RNA processing and neurodegeneration","author":"Lagier-Tourenne","year":"2010","journal-title":"Hum Mol Genet"},{"key":"key-10.4103\/0253-7613.276050-38","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/jcmm.13976","article-title":"MicroRNAs as regulators of cell death mechanisms in amyotrophic lateral sclerosis","author":"Gagliardi","year":"2019","journal-title":"J Cell Mol Med"},{"key":"key-10.4103\/0253-7613.276050-39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tins.2019.10.006","article-title":"Travelling together: A unifying pathomechanism for ALS","author":"Fratta","year":"2020","journal-title":"Trends Neurosci"},{"key":"key-10.4103\/0253-7613.276050-40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005072-198409000-00002","article-title":"Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis","author":"Hirano","year":"1984","journal-title":"J Neuropathol Exp Neurol"},{"key":"key-10.4103\/0253-7613.276050-41","first-page":"283","article-title":"Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research?","author":"De","year":"2017","journal-title":"Neurobiol Dis"},{"key":"key-10.4103\/0253-7613.276050-42","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/hmg\/ddt028","article-title":"Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS","author":"Taes","year":"2013","journal-title":"Hum Mol Genet"},{"key":"key-10.4103\/0253-7613.276050-43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2174\/1871527318666190409103831","article-title":"Targeting macrophage for the treatment of amyotrophic lateral sclerosis","author":"Li","year":"2019","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"key-10.4103\/0253-7613.276050-44","doi-asserted-by":"crossref","unstructured":"Jiang J, Ravits J. Pathogenic mechanisms and therapy development for C9orf72 amyotrophic lateral sclerosis\/frontotemporal dementia. Neurotherapeutics 2019. p. 1-18.","DOI":"10.1007\/s13311-019-00797-2"},{"key":"key-10.4103\/0253-7613.276050-45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mito.2019.07.003","article-title":"Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling","author":"Wu","year":"2019","journal-title":"Mitochondrion"},{"key":"key-10.4103\/0253-7613.276050-46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/1570159X16666180315142137","article-title":"Current therapeutic molecules and targets in neurodegenerative diseases based on in silico drug design","author":"Sehgal","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"key-10.4103\/0253-7613.276050-47","doi-asserted-by":"crossref","unstructured":"Lepore E, Casola I, Dobrowolny G, Musar\u00f2 A. Neuromuscular Junction as an Entity of Nerve-Muscle Communication. Cells 2019;8. pii: E906.","DOI":"10.3390\/cells8080906"},{"key":"key-10.4103\/0253-7613.276050-48","first-page":"S233","article-title":"The pharmacology and mechanism of action of riluzole","author":"Doble","year":"1996","journal-title":"Neurology"},{"key":"key-10.4103\/0253-7613.276050-49","first-page":"25","article-title":"Edaravone (Radicava): A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis","author":"Cruz","year":"2018","journal-title":"P T"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:37:52Z","timestamp":1786732672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_823_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"alternative-id":["276050"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_823_19","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}